Patent intelligence · US
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
Patent details — US 11407759
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 9, 2022
- Expiration
- Aug 4, 2042
- Applicant
- ACTUATE THERAPEUTICS INC.
- Claims
- 18
- CPC classes
- A61P, A61P35/00
Quick answer
US 11407759 (Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACTUATE THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P35/00
More from ACTUATE THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12116374
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12083098
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
granted -
US 11980607
Methods of treating malignant lymphoproliferative disorders
granted -
US 11510904
Methods of treating malignant lymphoproliferative disorders
granted -
US 11136334
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted
Frequently asked questions
What is US patent 11407759?
US 11407759 (Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11407759?
ACTUATE THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11407759 expire?
Our index shows an expiration date of Aug 4, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.